Phase IV adaptive randomised clinical trials evaluating efficacy and cost-efficacy of pre-emptive pharmacogenetic genotyping strategies in the Spanish National Health System: iPHARMGx Master Protocol and PREVESTATGx nested clinical trial.
Stewart S, Seco-Meseguer E, Diago-Sempere E, Marín-Candón A, Carmona M, Estébanez M, López-Fernández LA, Imaz-Iglesia I, Del Mar García Saiz M, Laserna-Mendieta EJ, Peiró AM, Farré M, Rodriguez-Jimenez C, Saiz-Rodriguez M, Sanabria-Cabrera J, Rosas-Alonso R, Abad-Santos F, Pedrosa L, Carcas AJ, García García I, Borobia AM; iPHARMGx study group.
Stewart S, et al. Among authors: garcia garcia i.
BMJ Open. 2024 Nov 7;14(11):e089823. doi: 10.1136/bmjopen-2024-089823.
BMJ Open. 2024.
PMID: 39510769
Free PMC article.